CORRIGENDUM

Lejeune T, Khatkova S., Turner-Stokes L., Picaut P., Maisonobe P., Balcaitiene J., Boyer F.C., *AbobotulinumtoxinA injections in shoulder muscles to improve adult upper limb spasticity: Results from a phase 4 real-world study and a phase 3 open-label trial.* J Rehabil Med 2020; 52: jrm00068

The authors have unfortunately discovered that the originally published version of this article contains errors, due to incorrect data published in this manuscript. These errors lead to minor changes of the paper, but need to be corrected.

In this corrigendum, we supply the corrected data in Fig. 4 (Cycle 3, Cycle 4 and Last Cycle), updated results section and also corrected data in Table SI.

RESULTS

In the Results section the following paragraph is changed.

Original paragraph

In the AUL open-label study, of the 254 patients receiving treatment in the upper limb muscles, 96 (37.7%) received abobotulinumtoxinA injection into a shoulder muscle at one or more treatment cycles. The majority of these patients ($n=84$) received at least 2 shoulder muscle injections. At baseline, patient and disease characteristics were comparable between the shoulder and non-shoulder populations (Table IB).

Corrected paragraph

In the AUL open-label study, of the 254 patients receiving treatment in the upper limb muscles, 96 (37.8%) received abobotulinumtoxinA injection into a shoulder muscle at one or more treatment cycles. The majority of these patients ($n=84$) received at least 2 shoulder muscle injections. At baseline, patient and disease characteristics were comparable between the shoulder and non-shoulder populations (Table IB).

Fig. 4.



Table SI. Doses of abobotulinumtoxinA injected in each shoulder muscle in the (A) Upper Limb International Spasticity-II (ULIS-II) study and (B) Adult Upper Limb (AUL) open-label study

(A) Shoulder muscles	ULIS-II study $n=82$
Pectoralis major, *n* (%)	63 (76.8)
Units, median (IQR) [range]	200.0 (150.0) [30–750]
Deltoideus, *n* (%)	14 (17.1)
Units, median (IQR) [range]	100.0 (100.0) [50–300]
Triceps brachii, *n* (%)	10 (12.2)
Units, median (IQR) [range]	175.0 (100.0) [60–300]
Subscapularis, *n* (%)	8 (9.8)
Units, median (IQR) [range]	200.0 (100.0) [75–320]
Teres major, *n* (%)	7 (8.5)
Units, median (IQR) [range]	75.0 (50.0) [50–200]
Rhomboids, *n* (%)	6 (7.3)
Units, median (IQR) [range]	150.0 (0) [150–400]
Latissimus dorsi, *n* (%)	3 (3.7)
Units, median (IQR) [range]	120.0 (125.0) [75–200]
Trapezius upper, *n* (%)	3 (3.7)
Units, median (IQR) [range]	100.0 (100.0) [100–200]
Supraspinatus, *n* (%)	1 (1.2)
Units, median (IQR) [range]	100.0 (0) [100–100]
Teres minor, *n* (%)	1 (1.2)
Units, median (IQR) [range]	100.0 (0) [100–100]

(B)	AUL open-label study			
Shoulder muscles	Cycle 1 $n=35$	Cycle 2 $n=67$	Cycle 3 $n=57$	Cycle 4 $n=33$
Pectoralis major, *n* (%)	23 (65.7)	52 (77.6)	48 (84.2)	30 (90.9)
Mean (SD) [range]	168.3 (47.5) [100–260]	226.0 (52.1) [100–300]	227.7 (65.3) [100–500]	224.0 (69.4) [100–500]
Latissimus dorsi, *n* (%)	11 (31.4)	31 (46.3)	32 (56.1)	13 (39.4)
Mean (SD) [range]	200 (0) [200–200]	194.5 (70.6) [100–400]	193.4 (65.5) [0–300]	175.4 (51.7) [100–260]
Triceps brachii, *n* (%)	12 (34.3)	29 (43.3)	23 (40.4)	10 (30.3)
Mean (SD) [range]	150.0 (67.4) [100–300]	184.8 (69.2) [80–300]	186.1 (58.9) [100–300]	194.0 (92.9) [80–300]
Subscapularis, *n* (%)	4 (11.4)	17 (25.4)	18 (31.6)	10 (30.3)
Mean (SD) [range]	175.0 (50) [100–200]	147.6 (59.5) [100–300]	122.8 (60.6) [0–260]	130.0 (48.3) [100–200]

IQR: interquartile range; SD: standard deviation.

doi: 10.2340/16501977-2830